NO971539L - Behandling av multippel sklerose (MS) og andre demyelinerende tilstander ved bruk av lofepramin i kombinasjon med L-fenylalanin tyrosin eller tryptofan og eventuelt en vitamin B12-forbindelse - Google Patents

Behandling av multippel sklerose (MS) og andre demyelinerende tilstander ved bruk av lofepramin i kombinasjon med L-fenylalanin tyrosin eller tryptofan og eventuelt en vitamin B12-forbindelse

Info

Publication number
NO971539L
NO971539L NO971539A NO971539A NO971539L NO 971539 L NO971539 L NO 971539L NO 971539 A NO971539 A NO 971539A NO 971539 A NO971539 A NO 971539A NO 971539 L NO971539 L NO 971539L
Authority
NO
Norway
Prior art keywords
combination
multiple sclerosis
lofepramine
tryptophan
vitamin
Prior art date
Application number
NO971539A
Other languages
English (en)
Other versions
NO971539D0 (no
NO314486B1 (no
Inventor
Cari Loder
Original Assignee
Cari Loder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420116A external-priority patent/GB9420116D0/en
Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en
Application filed by Cari Loder filed Critical Cari Loder
Publication of NO971539D0 publication Critical patent/NO971539D0/no
Publication of NO971539L publication Critical patent/NO971539L/no
Publication of NO314486B1 publication Critical patent/NO314486B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Control Of El Displays (AREA)
NO19971539A 1994-10-05 1997-04-04 Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform NO314486B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420116A GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GBGB9508482.8A GB9508482D0 (en) 1995-04-26 1995-04-26 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product
PCT/GB1995/002361 WO1996011009A1 (en) 1994-10-05 1995-10-05 Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound

Publications (3)

Publication Number Publication Date
NO971539D0 NO971539D0 (no) 1997-04-04
NO971539L true NO971539L (no) 1997-04-04
NO314486B1 NO314486B1 (no) 2003-03-31

Family

ID=26305745

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971539A NO314486B1 (no) 1994-10-05 1997-04-04 Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform

Country Status (19)

Country Link
US (2) US6096737A (no)
EP (1) EP0784476B1 (no)
JP (1) JPH10508583A (no)
AT (1) ATE227124T1 (no)
AU (1) AU710339B2 (no)
CA (1) CA2200761C (no)
CZ (1) CZ293873B6 (no)
DE (1) DE69528773T2 (no)
DK (1) DK0784476T3 (no)
ES (1) ES2184808T3 (no)
FI (1) FI116659B (no)
HU (1) HU225493B1 (no)
IS (1) IS1956B (no)
NO (1) NO314486B1 (no)
NZ (1) NZ293642A (no)
PL (1) PL181802B1 (no)
PT (1) PT784476E (no)
SK (1) SK281932B6 (no)
WO (1) WO1996011009A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69715899T2 (de) * 1996-07-05 2003-05-28 The Wwk Trust, Kent Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
EP0835660A1 (en) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) * 1999-02-24 1999-04-21 Worsley Andrew P Composition for the treatment of pain
GB9906808D0 (en) * 1999-03-24 1999-05-19 Kilgowan Limited Formulation for treatment of pain
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
AU2001279313B2 (en) 2000-08-04 2007-03-01 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) * 2002-03-14 2004-12-21 Duane Bennett Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
ATE520981T1 (de) 2002-10-02 2011-09-15 Dmi Biosciences Inc Diagnose und überwachung von krankheiten
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
CA3050734A1 (en) 2003-05-15 2004-12-02 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ATE552832T1 (de) 2006-02-24 2012-04-15 Shire Llc Antidepressivum-propharmaka
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
EA027343B1 (ru) 2011-10-10 2017-07-31 Ампио Фармасьютикалз, Инк. Имплантируемые устройства медицинского назначения с повышенной иммунной толерантностью и способы изготовления и имплантирования
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
CA2846394A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
AU2015305611B2 (en) 2014-08-18 2020-04-23 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
GB2544630A (en) 2015-11-19 2017-05-24 The Wwk Trust Combinations for the treatment of dementia, and the enhancement of cognitive function
WO2018076108A1 (en) * 2016-10-25 2018-05-03 Uti Limited Partnership Treatment for progressive multiple sclerosis
WO2018200381A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP3431491A1 (en) * 2017-07-18 2019-01-23 Centre National De La Recherche Scientifique Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497306A (en) * 1975-07-03 1978-01-05 Leo Ab Preparation of lofepramine and its hydrochloride
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4409243A (en) * 1981-11-09 1983-10-11 Julian Lieb Treatment of auto-immune and inflammatory diseases
GB2129299A (en) * 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (de) * 1992-02-12 1998-09-24 Kragler Peter Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen

Also Published As

Publication number Publication date
DE69528773T2 (de) 2003-09-04
HU225493B1 (en) 2007-01-29
NO971539D0 (no) 1997-04-04
SK43897A3 (en) 1998-08-05
AU3612695A (en) 1996-05-02
PT784476E (pt) 2003-03-31
FI971290A0 (fi) 1997-03-26
ES2184808T3 (es) 2003-04-16
US6096737A (en) 2000-08-01
HUT77380A (hu) 1998-04-28
WO1996011009A1 (en) 1996-04-18
US6569850B1 (en) 2003-05-27
AU710339B2 (en) 1999-09-16
EP0784476A1 (en) 1997-07-23
ATE227124T1 (de) 2002-11-15
NO314486B1 (no) 2003-03-31
NZ293642A (en) 1998-10-28
IS4454A (is) 1997-03-26
FI971290L (fi) 1997-06-02
FI116659B (fi) 2006-01-31
EP0784476B1 (en) 2002-11-06
CA2200761C (en) 2008-02-26
CZ99597A3 (en) 1997-11-12
SK281932B6 (sk) 2001-09-11
IS1956B (is) 2004-11-15
DE69528773D1 (de) 2002-12-12
DK0784476T3 (da) 2003-03-17
PL181802B1 (en) 2001-09-28
JPH10508583A (ja) 1998-08-25
PL319830A1 (en) 1997-09-01
CZ293873B6 (cs) 2004-08-18
CA2200761A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
NO971539D0 (no) Behandling av multippel sklerose (MS) og andre demyelinerende tilstander ved bruk av lofepramin i kombinasjon med L-fenylalanin tyrosin eller tryptofan og eventuelt en vitamin B12-forbindelse
SG43768A1 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative dieases
MX9707665A (es) Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas.
NO960339L (no) Fremgangsmåte for å inhibere restenose
IL117799A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
DE69622265D1 (de) Trizyklische verbindungen zur behandlung von zellproliferativen störungen
PT942751E (pt) Composicoes para o tratamento de neuropatias perifericas contendo antiodepressivos e/ou inibidores da monoamino-oxidase e/ou vitamina b12 e/ou precursores ou indutores de neurotransmissores
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
DE69400631D1 (de) Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose
DK0910428T3 (da) Fotoferesebehandling af kroniske HCV-infektioner
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
EA199800160A1 (ru) Фармацевтическая композиция для лечения сердечно-сосудистых заболеваний, содержащая 3-(2,2,2-триметилгидразиний)пропионат и гамма-бутиробетаин
EA199800317A1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
DK0859630T3 (da) Kombination af termozolomid og alfa-IFN til behandling af fremskreden cancer
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
KR960003741A (ko) 조골세포 증식인자
UA10928C2 (uk) Спосіб профілактики гіперхолестериhемії
RU94033502A (ru) Способ лечения детей, больных вторичным панкреатитом
UA28288A (uk) Спосіб лікування шизофренії
UA19610A (uk) Спосіб лікуваhhя опісторхозhої іhвазії
RU94045317A (ru) Способ лечения вилюйского энцефаломиелита
RU95108457A (ru) Способ лечения тяжелых форм глпс
UA8278A (uk) Спосіб лікування псоріазу

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees